Roth Capital Expects Weaker Earnings for Sensus Healthcare

Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - Research analysts at Roth Capital lowered their Q4 2025 earnings per share (EPS) estimates for Sensus Healthcare in a note issued to investors on Thursday, August 7th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings of $0.13 per share for the quarter, down from their previous forecast of $0.18. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.32 per share.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.07). Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.56%. The company had revenue of $7.32 million for the quarter, compared to the consensus estimate of $9.30 million.

Other equities analysts have also issued research reports about the company. Lake Street Capital dropped their price objective on Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating for the company in a research note on Friday, August 8th. HC Wainwright decreased their target price on Sensus Healthcare from $12.00 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday. Wall Street Zen downgraded Sensus Healthcare from a "hold" rating to a "sell" rating in a research report on Sunday, June 22nd. Finally, Maxim Group decreased their target price on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, May 19th.

Sensus Healthcare Price Performance

Shares of NASDAQ SRTS remained flat at $3.42 during mid-day trading on Monday. The stock had a trading volume of 111,929 shares, compared to its average volume of 193,206. The company has a market cap of $56.22 million, a price-to-earnings ratio of -57.00 and a beta of 1.34. The firm's 50 day simple moving average is $4.75 and its two-hundred day simple moving average is $4.93. Sensus Healthcare has a 1 year low of $3.03 and a 1 year high of $9.33.

Institutional Trading of Sensus Healthcare

Institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. purchased a new position in Sensus Healthcare in the 4th quarter worth $27,000. Barclays PLC purchased a new position in Sensus Healthcare in the 4th quarter worth $35,000. Larson Financial Group LLC purchased a new position in Sensus Healthcare in the 1st quarter worth $26,000. BNP Paribas Financial Markets purchased a new position in Sensus Healthcare in the 4th quarter worth $47,000. Finally, Vise Technologies Inc. purchased a new position in Sensus Healthcare in the 2nd quarter worth $52,000. Institutional investors and hedge funds own 25.30% of the company's stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.